Aguiar, Pedro, Jr.De Mello, Ramon AndradeTadokoro, HakaruBabiker, HaniLopes, Gilberto2019-11-202019-11-202017-011556-08641556-1380http://hdl.handle.net/10400.1/13305Delivering high quality cancer care at an affordable cost is one of the main challenges for health care professionals and policy makers, especially in lowand middle-income countries. The objective of our study is to assess the economic impact of nivolumab and pembrolizumab with and without the use of PD-L1 as a biomarker in Brazil.engconference object